As a result, when the heart doesn't efficiently pump the blood forward with strong contractions, symptoms develop because:. View an animation of a normal heartbeat. The amount of blood pumped out of the ventricles to the body is based on the randomness of the atrial beats. The body may get rapid, small amounts of blood and occasional larger amounts of blood.
The amount will depend on how much blood has flowed from the atria to the ventricles with each beat. However, it is still something you and your healthcare provider will want to monitor for because some people live with AFib and do not feel the symptoms.
However, the risks are still present. Overall, most of the risks, symptoms and consequences of AFib are related to how fast the heart is beating and how often rhythm disturbances occur.
AFib may be brief, with symptoms that come and go. It is possible to have an atrial fibrillation episode that resolves on its own. Or, the condition may be persistent and require treatment.
Sometimes AFib is permanent, and medicines or other treatments can't restore a normal heart rhythm. But for all the reasons listed above, it is important to work with your healthcare provider to determine your treatment needs, and to understand your treatment options. It is also important to maintain a heart-healthy lifestyle and reduce your overall risks as much as possible.
Written by American Heart Association editorial staff and reviewed by science and medicine advisers. See our editorial policies and staff. Atrial Fibrillation. When the upper chambers of the heart atria do not pump efficiently, as in atrial fibrillation, there's a risk of blood clots forming. These blood clots may move into the lower chambers of the heart ventricles and get pumped into the blood supply to the lungs or the general blood circulation. Clots in the general circulation can block arteries in the brain, causing a stroke.
Curr Cardiol Rev ; 9 : — What are the costs of heart failure? Europace ; 13 Suppl. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease Study. Circulation ; : — Estimates of current and future incidence and prevalence of atrial fibrillation in the U. Am J Cardiol ; : — Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol ; 6 : — Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry.
Circ Arrhythm Electrophysiol ; 5 : — Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey.
Eur J Heart Fail ; 16 : — Am J Med ; : — Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.
Am J Cardiol ; 91 : 2D — 8D. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail ; 11 : — Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet ; : — Increased mortality after dronedarone therapy for severe heart failure.
Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. J Am Coll Cardiol ; 64 : — Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation.
J Am Coll Cardiol ; 59 : — Mechanisms of conduction slowing during myocardial stretch by ventricular volume loading in the rabbit. J Am Coll Cardiol ; 53 : — Relevance of electrical remodeling in human atrial fibrillation: results of the asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial mechanisms of atrial fibrillation study. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
Repolarization alternans reveals vulnerability to human atrial fibrillation. Atrial fibrillation in heart failure: a comprehensive review. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia.
Cardiac performance early after cardioversion from atrial fibrillation. Am Heart J ; : — Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis.
J Am Coll Cardiol ; 55 : — Blockade of the renin-angiotensin-aldosterone system RAAS for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.
Int J Cardiol ; : 17 — Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity CHARM program. Am Heart J ; : 86 — The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology.
Eur Heart J ; 35 : — Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med ; : — Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population.
Stroke ; 37 : — The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther ; 36 : — Apixaban in patients with atrial fibrillation. Apixaban versus warfarin in patients with atrial fibrillation. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Dabigatran versus warfarin in patients with atrial fibrillation. Edoxaban versus warfarin in patients with atrial fibrillation.
Eur Heart J ; 33 : — Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension. J Heart Lung Transplant ; 33 : — Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity CHARM program.
J Am Coll Cardiol ; 47 : — Irbesartan in patients with atrial fibrillation. JAMA ; : — Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. Syst Rev ; 2 : 7. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
Circ Heart Fail ; 5 : — The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Eplerenone in patients with systolic heart failure and mild symptoms. Rhythm control versus rate control for atrial fibrillation and heart failure. Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction.
A systematic review and meta-analysis. J Card Fail ; 17 : — Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol ; 61 : — Developed with the special contribution of the European Heart Rhythm Association.
Safety and efficacy of digoxin therapy: a systematic review and meta-analysis of observational and controlled trial data. BMJ ; : h Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol ; 42 : — Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation ; 83 : 52 — Secondary prevention with verapamil after myocardial infarction.
Am J Cardiol ; 66 : 33 — The evidence regarding the drugs used for ventricular rate control. Kumar K. Overview of atrial fibrillation. Accessed Aug. Bonow RO, et al. Atrial fibrillation: Clinical features, mechanisms and management.
January CT, et al. Catheter ablation. Accessed Jan. High blood pressure, Afib, and your risk of stroke. American Heart Association. Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations.
Ganz LI. Control of ventricular rate in atrial fibrillation: Pharmacologic therapy. Reddy VY, et al. Journal of the American College of Cardiology. Braswell Pickering EA. Allscripts EPSi. Mayo Clinic. July 22, Noseworthy PA expert opinion. Guide to atrial fibrillation. Heart Rhythm Society. Related Atrial fibrillation Atrial fibrillation and managing stress Caregiving for someone with atrial fibrillation Catheter ablation to isolate the pulmonary veins to treat atrial fibrillation Does atrial fibrillation run in families?
0コメント